As a result of their close association with the blood-brain barrier, astrocytes play an important role in regulating the homing of different leukocyte subsets to the inflamed central nervous system (CNS). In this study, we investigated whether human astrocytes produce chemokines that promote the migration of myeloid dendritic cells (DCs). By reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay, we show that cultured human astrocytes stimulated with interleukin-1b and tumor necrosis factor produce CCL2, CCL3, CCL4, CCL5, CCL20, and CXCL12 that act on immature DCs, but not CCL19 and CCL21, 2 chemokines specific for mature DCs. Compared with controls, supernatants of cytokine-stimulated astrocytes are more effective in promoting the migration of immature monocyte-derived DCs (iMDDCs). Desensitization of CXCR4 (receptor for CXCL12), CCR1-3-5 (shared receptors for CCL3-4-5), and CCR6 (receptor for CCL20) on iMDDC reduces cell migration toward astrocyte supernatants, indicating that astrocytes release biologically relevant amounts of iMDDC-attracting chemokines. By immunohistochemistry, we show that CXCL12 and, to a lesser extent, CCL20 are expressed by reactive astrocytes in multiple sclerosis lesions. These data lend support to the idea that astrocyte-derived chemokines may contribute to immature DC recruitment to the inflamed CNS.
INTRODUCTION
Dendritic cells (DCs) represent the most efficient population of antigen-presenting cells with a key role in both the tolerization to self-peptides and the induction of immunity against foreign antigens (1, 2) . As sentinels of the immune system, DCs are present in most of the body organs and fluids in an immature phenotype, ready to take up and process antigens and to migrate after maturation to lymphoid organs, where they present antigens to and activate T cells. Depending on their number, maturation state, and cytokine profile, DCs are able to stimulate naive T lymphocytes and to drive their differentiation into functionally different populations of effector and regulatory T cells and to cross present exogenous antigens bound to MHC class I molecules (3, 4) .
The central nervous system (CNS) qualifies as an immune-privileged site as a result of the absence of identifiable DCs and conventional lymphatic vessels in the neural parenchyma. However, the presence of resident DCs in the meninges and choroid plexus (5) , coupled with the knowledge that cerebrospinal fluid and brain interstitial fluid can drain into cervical lymphatics (6) , indicates that the CNS is constantly under immune surveillance and provides an explanation for the rapid triggering of immune responses after injection of foreign antigens in the ventricular compartment (7) . Recent studies indicate that DCs are recruited to the CNS in a variety of inflammatory and neurodegenerative conditions, including bacterial and parasitic infections (8, 9) , ischemia (10, 11) , amyotrophic lateral sclerosis (12) , multiple sclerosis (MS) (13) (14) (15) and its animal model experimental autoimmune encephalomyelitis (EAE) (8, 16, 17) . DCs accumulating in the cerebrospinal fluid and around meningeal and intraparenchymal blood vessels display both an immature and mature phenotype (13) (14) (15) (16) (17) (18) , and are thought to play an important role in increasing the efficiency of antigen presentation and lymphocyte activation at the tissue level or after migration to cervical lymph nodes (19) . The source(s) and nature of the chemotactic signals regulating DC recruitment and retention into the CNS are still largely unknown, and their comprehension could provide important clues to the identification of new molecular targets for the therapy of neuroinflammatory diseases.
Chemokines are a large family of small, secreted proteins that regulate the migration of distinct leukocyte subsets to inflamed and noninflamed tissues and are involved in the development, homeostasis, and functional organization of lymphoid and nonlymphoid tissues (20) (21) (22) . Chemokines are produced by different cell types, either constitutively or on stimulation by infectious and inflammatory stimuli, and signal through binding to specific, often promiscuous receptors that are differentially expressed on the surface of immune and nonimmune cell populations. Recently, evidence has emerged that immature and mature DCs display a different pattern of chemokine receptors and respond to different sets of chemokines. Immature DCs respond to many CC-chemokines such  as CCL2, CCL3, CCL4, CCL5, CCL7, CCL13, CCL15, CCL18,  CCL20, CCL22 , and CCL25 and to CXCL12 (23) (24) (25) (26) (27) (28) . These chemokines regulate DC migration from the blood to nonlymphoid and lymphoid tissues under physiological and pathologic conditions. Conversely, mature DCs migrating from tissues to draining lymph nodes through lymphatic vessels loose their responsiveness to most of the chemokines mentioned and acquire responsiveness to the lymphoid homing chemokines CCL19 and CCL21 as a consequence of CCR7 receptor upregulation (29, 30) .
The aim of this study was to investigate whether astrocytes, the major CNS glial cell population, release DC-attracting chemokines. Owing to the strategic location of their end-foot processes at the blood-brain barrier and beneath the pia (glia limitans), astrocytes can be viewed as the CNS surface-lining cells and exert an important regulatory influence on leukocyte homing into the brain/spinal cord. Astrocytes from different sources have been shown to release a variety of chemokines, both in the presence of activating stimuli in vitro and in neuroinflammatory conditions in vivo (31, 32) .
In the present study, we report that cultured human astrocytes stimulated with interleukin-1beta (IL-1b) and tumor necrosis factor (TNF) express mRNA for and release a number of chemokines known to be active on immature DCs. In standard chemotaxis experiments, we demonstrate that astrocytes produce biologically relevant amounts of CCR5 ligands (CCL3, CCL4, CCL5), CCL20, and CXCL12, which are able to promote the in vitro migration of human immature monocytederived dendritic cells (iMDDCs). To investigate the functional relevance of DC-attracting chemokines, whose expression in the diseased human brain is still poorly characterized, we analyzed the immunohistochemical distribution of CCL20 and CXCL12 in brain tissue from control individuals and patients with MS. Evidence is provided that in chronic MS lesions, CXCL12 is mainly produced by astrocytes and endothelial cells, whereas CCL20 is expressed by foamy macrophages and a few astrocytes. Altogether, these data lend support to the hypothesis of an active participation of astrocytes in the regulation of DC recruitment to the brain tissue, an event that is likely to be important for the onset and progression of CNS autoimmune diseases.
MATERIALS AND METHODS

Glial Cell Cultures
Human fetal astrocyte cultures were established as previously described (33) . Astrocyte-enriched populations obtained from second-passage cell cultures were stored in liquid nitrogen and, after thawing, were grown for an additional 2 to 3 days in Basal Medium Eagle's containing 10% fetal calf serum (FCS) (GIBCO, Paisley, UK). These tertiary cultures contained 75% to 90% glial fibrillary acidic protein (GFAP)-positive (+) cells, 2% fibronectin+ fibroblasts, 1% neurofilament+ neurons, 8% to 18% vimentin+ neural progenitors, but no CD14+ microglia or O4+ oligodendrocytes.
Generation of Immature Monocyte-Derived Dendritic Cells
iMDDCs were prepared as previously described (34) . Briefly, monocytes were purified by positive sorting using anti-CD14-conjugated magnetic microbeads (Miltenyi, Bergisch Gladbach, Germany). iMDDCs were generated by culturing monocytes in 6-well tissue culture plates with 25 ng/mL GM-CSF (Schering-Plough, Dardilly, France) and 1000 U/mL of IL-4 (R&D Systems, Abingdon, UK) for 5 days at a density of 0.5 3 10 6 cells/mL in RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 15% FCS (all these reagents were from BioWhittaker, Europe, Verviers, Belgium). At day 5, cells were 70% to 90% CD1a+ and CD14-negative. Before the chemotaxis assays, cells were starved from IL-4 and GM-CSF and resuspended in fresh medium.
RNA Extraction and RNase Protection Assay
RNA was extracted from astrocyte cultures that were maintained for 24 hours in either control medium (BME + 1% FCS) or in the same medium containing TNF (20 ng/mL) and IL-1b (50 U/mL) (Peprotech, London, UK) by using an RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. RNase protection assay was performed as previously described (34) . The hCK-5 and hCK-9 multiprobe template sets (RiboQuant; BD PharMingen, San Diego, CA) were used to analyze chemokine expression. A sample containing 5 mg of yeast tRNA was used as negative control for nonspecific contamination.
Chemokine Detection
Supernatants from control and cytokine-treated astrocyte cultures were harvested and tested for chemokine production by enzyme-linked immunosorbent assays (ELISAs). ELISA kits for CXCL12, CCL3, CCL4, CCL5, and CCL20 were obtained from R&D Systems. All procedures were performed according to the manufacturer's instructions. Supernatants from 4 different astrocyte cultures were analyzed.
Chemotaxis Assay
Chemotaxis assay was performed using 8-mm-pore polycarbonate filters in 24-well Transwell chambers (Costar, St. Louis, MO), as previously described (34) . iMDDCs were washed and resuspended at a density of 2 3 10 6 /mL in RPMI + 1% FCS. The supernatants from controls and IL-1b + TNFstimulated astrocyte cultures (same cytokine concentrations as described) were diluted 1:3 in BME + 1% FCS and added to the bottom chambers of the Transwell apparatus. Resuspended iMDDCs (2 3 10 5 cells in 100 mL) were then plated into the top chambers and the plates were incubated for 4 hours at 37°C. Migrated cells were counted with a flow cytometer (FACSCalibur; Becton Dickinson, Mountain View, CA) by 1-minute acquisition at a flow rate of 100 mL per minute with a continuous mixing. To desensitize the chemokine receptors CCR1, CCR3, CCR5, CCR6, and CXCR4, the iMDDCs were preincubated for 1 hour at 37°C with high amounts of CCL5 (ligand for CCR1, CCR3, and CCR5), CCL20, or CXCL12, respectively (10 mg/mL, from Peprotech), before the migration assay. As positive control, migration of iMDDCs was evaluated in the presence of CCL5, CCL20, and CXCL12 recombinant proteins (100 ng/mL). All experimental points were performed in duplicate.
FACS Analysis
iMDDCs (1 3 10 5 ) were aliquoted into tubes, washed once in phosphate-buffered saline (PBS) containing 2% FCS, and incubated with FITC-or PE-conjugated monoclonal antibodies (mAbs) specific for CD1a, CD14, and CCR6, and IgG1 and IgG2a isotype controls (all from BD Pharmingen) at 4°C for 45 minutes. The cells were then washed and fixed with 2% paraformaldehyde before analysis on a flow cytometer (FACSCalibur) using CellQuest software (BD Biosciences).
cDNA Preparation and Semiquantitative Reverse Transcriptase-Polymerase Chain Reaction
One microgram of RNA obtained from iMDDC was reverse-transcribed in a final volume of 50 mL containing 400 U of M-MMLV reverse transcriptase (RT) (Gibco-BRL Life Technologies Inc., Gaithersburg, MD), 2 U of RNase Block (Roche), 0.5 mM of a mix of dATP, dTTP, dCTP, dGTP (Gibco-BRL Life Technologies Inc.), 10 mM DTT, 1 mM of oligo dT, and RT buffer according to the manufacturer's instructions. Reverse transcription was carried out at 37°C for 90 minutes. Ten microliters and 1 mL of cDNA were amplified using specific primers for CCR6 and GAPDH, respectively. CCR6 primers were as follows: 5#-ATT TCA GCG ATG TTT TCG ACT C-3# forward and 5#-GGA GAA GCC TGA GGA CTT GTA-3# reverse primer (29) , GAPDH primers (purchased from Genenco) were as follows: 5#-GTC TTC ACC ATG GAG AAG GTC-3# forward and 5#-CAT GCC AGT GAG CTT CCC GTT CA-3# reverse. Polymerase chain reaction (PCR) reactions were performed in a total volume of 50 mL of 13 PCR buffer (10 mM Tris HCl, pH 8.3, 50 mM KCl) containing 1.5 U AmpliTaq Gold enzyme (5 U/mL; Applied Biosystems, Foster City, CA), 25 mM of MgCl 2 , 0.2 mM of each dNTP (Gibco-BRL Life Technologies), 5% DMSO, and 1 mM of each forward and reverse primer. For CCR6, the reaction mixture was subjected to 30 cycles of PCR in the following conditions: 94°C for 1 minute, 61.5°C for 2 minutes, and 72°C for 3 minutes. The PCR products were visualized on 1% agarose gels. As negative control, a PCR reaction was performed without addition of cDNA.
Multiple Sclerosis Patients and Tissues
We analyzed autopsic brain tissues obtained from one patient with primary progressive (PP) MS, 2 patients with secondary progressive (SP) MS, and one control subject who died of cardiac failure without signs of neurologic disease. All tissues were provided by the UK Multiple Sclerosis Tissue Bank. As control tissue, a tonsil from a child who had undergone tonsillectomy and a bioptic sample of human skin were used.
Immunohistochemistry for CXCL12 and CCL20 was performed on a total of 13 MS lesions (7 chronic inactive and 6 chronic active) from 6 different tissue blocks and on sections from the control brain. MS lesions were analyzed by histopathologic methods (that is, hematoxylin and eosin staining and the Luxol fast blue/Periodic acid-Schiff reaction) and classified using the staging system described by De Groot et al (35) . Areas far away from the lesions, showing no signs of demyelination by histology, were considered as normal-appearing white matter (NAWM) and analyzed in all the sections studied.
Immunohistochemistry
CNS tissues from MS and control subjects were removed between 10 and 24 hours postmortem, fixed in 4% paraformaldehyde for 15 days, passed in 15% and 30% sucrose, frozen by immersion in precooled isopentane (-55°C), and stored at -80°C until use. Bioptic tonsil and skin, used as control tissues, were fixed and frozen using the same protocol. Acetone-fixed, 10-mm-thick cryosections were immunostained with antihuman CXCL12 mAb (R&D Systems), anti-GFAP polyclonal Ab (Dako) to identify astrocytes, and anti-DC SIGN/CD209 mAb (BD Biosciences) to investigate the presence of immature dendritic cells. Sections were first subjected to the antigen retrieval procedure with microwave in citrate buffer 10 mM (pH 6.0) and then sequentially incubated with 0.1% H 2 O 2 in PBS to eliminate endogenous peroxidase activity, 10% of normal rabbit or goat serum for 1 hour, and with the primary antibodies appropriately diluted in PBS containing 1% BSA and 0.1% Triton X100 (except for CD209) overnight at 4°C. Binding of the biotinylated secondary Ab (rabbit antimouse IgG or goat antirabbit IgG, both from Jackson Immunoresearch Laboratories) was visualized with avidinbiotin horseradish peroxidase complex technique (ABC Vectastain Elite kit; Vector Laboratories, Burlingame, CA) and 3,3#-diaminobenzidine (DAB) (Sigma) as substrate. All sections were counterstained with hematoxylin, sealed with coverslips, and viewed and photographed with an Axiophot Zeiss microscope.
For double immunofluorescence stainings, acetone-fixed cryosections were subjected to the antigen retrieval procedure as described previously, and then sequentially incubated with 20% normal donkey serum for 1 hour, and with a combination of goat antihuman CCL20 (R&D system), diluted 1:30, and rabbit anticow GFAP polyclonal antibody or anti-CD68 mAb (both from Dako, Carpinteria, CA), diluted 1:300 and 1:50, respectively, in PBS + 2% BSA and 0.1% Triton X100 overnight at 4°C. After washing, a mixture of the secondary antibodies (fluorescein-conjugated donkey antigoat IgG and cy3-conjugated donkey antirabbit IgG or TRITC-conjugated donkey antimouse IgG; all from Jackson Laboratories) was applied for 1 hour at room temperature. Sections were sealed with 70% glycerol in PBS and images were acquired using a laser scanning confocal microscope (LSM 5 Pascal, Carl Zeiss). Negative controls included the use of IgG isotype controls and preimmune sera.
Statistical Analysis
The data are expressed as means 6 standard error. Statistical significance of differences was determined by paired 2-tailed Student t-test (p , 0.05 was considered significant).
RESULTS
Cytokine-Stimulated Human Astrocytes Produce Dendritic Cell-Attracting Chemokines
To investigate the ability of astrocytes to synthesize chemokines involved in the recruitment of DC, human astrocytes were grown in the absence or presence of IL-1b and TNF, 2 inflammatory cytokines known to stimulate chemokine production in this cell type (32, 36) . After 24 hours, cells and supernatants were collected and analyzed for gene and protein expression, respectively. By using RNase protection assay, we found that, compared with controls, astrocytes that had been treated simultaneously with IL-1b (50 U/mL) and TNF (20 ng/mL) for 24 hours expressed mRNAs encoding several inflammatory chemokines, namely CCL2, CCL4, CCL5, CCL20, CXCL8, and CXCL10 (Fig. 1A, B) . Weak induction of CCL3 mRNA was also observed. CCL2 was the only chemokine expressed at high levels already in basal culture conditions. Among the chemokines mentioned, CCL2, CCL3, CCL4, CCL5, and CCL20 are known to be active on human immature DCs (23, 24, 26) . Human astrocytes failed to express mRNAs for CCL15, CCL18, and CCL25, which have been reported to stimulate the migration of human immature DCs (24, 26, 28) , and for CCL19 and CCL21, 2 chemokines acting specifically on mature DCs (25, 26) . In agreement with previous findings obtained in mouse astrocytes (37) , mRNA for CCL22, a chemokine active on both immature and mature DCs (25, 38) , was not detected in cytokine-stimulated human astrocytes (Fig. 1) .
To further explore the secretion of DC-attracting chemokines, 24-hour supernatants from control and cytokine-stimulated human astrocytes were analyzed by ELISA assays. Production of CXCL12, a chemokine active on immature and mature DCs (24, 25, 39) that was not included in the multiprobe template sets used for RNase protection experiments, was also evaluated using a specific ELISA. The data shown in the Table indicate that untreated astrocytes secrete detectable amounts of CXCL12 but no CCL3, CCL4, CCL5, or CCL20 proteins. Stimulation with IL-1b/TNF induces production of CCL3, CCL4, CCL5, and CCL20, and enhances CXCL12 secretion by approximately 5-fold. CCL2 protein levels were not monitored because we had shown previously that human fetal astrocytes secrete elevated amounts of CCL2 (in the order of several nanogram per milliliter), both in basal conditions and after stimulation with IL-1b or TNF (40).
CCR5-Binding
Previous studies have demonstrated that iMDDC express CCR1, CCR3, CCR5, and CXCR4 and migrate in response to the corresponding chemokine ligands (24, 39, 41, 42) , whereas discrepant data have been published on the expression of the CCL20 receptor CCR6 by iMDDC and on their ability to migrate toward CCL20 (43, 44) . To clarify this issue, we first evaluated the presence of CCR6 in our iMDDC preparations by RT-PCR and FACS analysis. Because IL-4 is known to inhibit the expression of CCR6 in MDDC (45, 46) , at day 5, in vitro iMDDC were deprived of IL-4 and GM-CSF for 20 hours. After IL-4/GM-CSF starvation, a significant increase in CCR6 mRNA levels in iMDDC was observed by RT-PCR ( Fig. 2A) . CCR6 protein expression was also detected on the surface of starved iMDDC by FACS analysis (Fig. 2B) . Exposure of iMDDCs to CCL20 (100 ng/mL) elicited a 2-fold increase in the percentage of migrated cells compared to control medium confirming the presence of functionally active CCR6 on iMDDC (Fig. 3) . iMDDCs also showed significantly enhanced migration toward CXCL12, whereas a lower migratory response was induced by CCL5 (both chemokines were used at a concentration of 100 ng/mL) (Fig. 3) .
To investigate whether human astrocytes secrete biologically active chemokines able to promote the migration of iMDDC, supernatants from control and cytokine-stimulated FIGURE 1. Chemokine mRNA expression in human fetal astrocytes is induced by IL-1b and TNF. Astrocyte cultures were grown for 24 hours in medium without (Ctr) and with IL1b(50 U/mL) and TNF (20 ng/mL). Total RNA was isolated and the expression of different chemokines was analyzed by RNase protection assay (RPA) (5 mg) using hCK-5 (A) and hCK-9 (B) multiprobe template sets. C -is the negative control to check for possible nonspecific contamination. One representative RPA experiment out of 3 independent experiments with RNA extracted from different astrocyte cultures is shown. astrocyte cultures were also tested in chemotactic assays. Compared with cell-free medium, supernatants of unstimulated astrocytes enhanced iMDDC migration by 1.2-fold, whereas supernatants of IL-1b/TNF-treated astrocytes were even more effective (greater than 2-fold induction) (Fig. 3) . Preincubation of iMDDCs with a high dose of CCL5, CCL20, or CXCL12 protein (10 mg/mL), a treatment used to desensitize the corresponding receptors (CCR1/CCR3/CCR5, CCR6, and CXCR4, respectively) on target cells, significantly reduced cell migration induced by cytokine-stimulated astrocyte supernatants (Fig. 3) . This finding indicates that astrocyte-derived CCL5, CCL20, and CXCL12 are all involved in the stimulation of iMDDC migration. However, because CCR5 also binds CCL3 and CCL4, which are produced by astrocytes on exposure to IL-1b/TNF, the contribution of these chemokines to iMDDC migration cannot be excluded. Although CCL2 is abundantly produced by astrocytes, the migration toward this chemokine was not tested because iMDDC were previously reported to lack responsiveness to CCL2 (24, 26) .
CXCL12 and CCL20 Are Expressed in Astrocytes in Multiple Sclerosis Brain Lesions
To address the functional relevance of astrocyte-derived CXCL12 and CCL20 in the normal and inflamed CNS, the expression of these chemokines was evaluated in postmortem brain tissue from control patients and from patients with MS, a chronic inflammatory disease characterized by accumulation of activated lymphocytes, macrophages, and dendritic cells in the cerebrospinal fluid, white matter, and meninges (47) . In control brain and NAWM of MS brains, CXCL12 immunoreactivity was detected in cerebrovascular endothelial cells but not in glial cells (Fig. 4A, B) . Several cortical neurons were also immunopositive for CXCL12 (data not shown). In all MS brain tissue blocks examined, a strong CXCL12 immunoreactivity /well) toward CCL5, CCL20, and CXCL12 recombinant proteins (100 ng/mL) or toward supernatants from control and IL-1b + TNF-treated astrocyte cultures was evaluated. To desensitize CCR1,3,5, CCR6, and CXCR4 receptors, cells were preincubated for 1 hour at 37°C with saturating doses of CCL5, CCL20, and CXCL12 (10 mg/mL), respectively. Values indicate fold induction over spontaneous migration toward RPMI containing 1% FCS (cell-free control medium). Values are means (6standard error) of 5 experiments performed in duplicate. The percentage of migrated iMDDC toward cell-free control medium was 5.8% 6 1.8% of the input cells. *a, p , 0.05; statistical significance was calculated versus cell-free control medium. *b, p , 0.05; statistical significance was calculated versus supernatants from untreated astrocytes. *c, p , 0.05 and **, p , 0.02; statistical significance was calculated versus iMDDC that were preexposed to high chemokine doses (see previously).
was present in the white matter parenchyma, predominantly associated with cells exhibiting a typical astrocytic morphology (Fig. 4C ). Astrocytes were identified as a cellular source of CXCL12 by comparing serial sections stained for the astrocytic marker GFAP (Fig. 4D) . The highest density of CXCL12-positive astrocytes was found at the margins of chronic active subcortical lesions in patients with SP MS (Fig. 4C) . In these areas, the dendritic cell marker DC-SIGN/CD209 was found to be expressed in several cells within the perivascular inflammatory infiltrates (Fig. 4E) . Increased expression of CXCL12 was also detected in vascular endothelial cells and some macrophages present in areas of intense immunologic activity at the lesion borders (data not shown). In brain sections from a patient with PP MS, in whom several actively demyelinating lesions were observed, CXCL12 was expressed by astrocytes as well as by macrophages and activated microglia within and at edges of the chronic active lesions (Fig. 4F) . Also in these lesions, perivascular DC-SIGN/CD209+ DCs were identified (data not shown).
The expression pattern of CCL20 in MS and control brains was analyzed using immunofluorescence techniques. Double stainings with anti-CCL20 and anti-GFAP polyclonal antibody or anti-CD68 mAb were performed on sections consecutive to those used for CXCL12 immunolocalization. No CCL20 staining was found in control brain tissue (data not shown). In patients with SP MS, several CCL20+/GFAP+ astrocytes were observed at the edge of chronic active and inactive subcortical lesions (Fig. 5A) , whereas no CCL20 expression was detected in the NAWM (Fig. 5B) . At the borders of chronic active lesions, several CCL20+ macrophages were also observed (data not shown). In the patient with PP MS, CCL20 immunoreactivity was detected in a few reactive GFAP+ astrocytes within the damaged white matter (Fig. 5C ) and in numerous CD68+ foamy macrophages distributed along the active lesion borders and around inflamed blood vessels (Fig. 5D) . In these lesions, CCL20 immunoreactivity was also occasionally found in ramified cells resembling activated microglia (data not shown).
DISCUSSION
In this study, we explored whether astrocytes might contribute to the recruitment of DCs into the inflamed CNS through the release of DC-attracting chemokines. In vitro experiments showed that human astrocytes stimulated with the macrophage-derived cytokines IL-1b and TNF express several chemokines, namely CCL2, CCL3, CCL4, CCL5, CCL20, and CXCL12, which have been implicated in the migration of immature DCs (23) (24) (25) (26) (27) (28) . CXCL12 has been shown to act also on mature DCs (39) . Experiments of receptor desensitization revealed that among the chemokines secreted by activated astrocytes, CCR5-binding chemokines, CCL20, and CXCL12 were effective in promoting the migration of immature DCs derived from human blood monocytes. We also found that CCL20 and CXCL12 are expressed in different cell types, including astrocytes, in MS lesions. Although we cannot exclude that in vivo astrocytes may take up or bind these chemokines, altogether these data suggest that in an inflammatory, cytokinerich environment astrocytes can provide chemotactic stimuli for the recruitment of antigen-presenting cells that are normally excluded from the CNS parenchyma. In MS, DC recruitment to the brain could break tolerance to CNS antigens and play a role in the onset and progression of autoimmune responses, which are thought to be fundamental for disease pathogenesis (48, 49) .
Expression of DC-attracting chemokines in endothelial cells, macrophages, and astrocytes in MS lesions is compatible with the presence of DCs in the perivascular cuffs of inflamed blood vessels. Both immature and mature DCs have been identified in the MS brain, indicating that the inflamed CNS microenvironment not only supports the migration of immature DCs, but also their retention and maturation (13) (14) (15) . Chemokines produced by astrocytes could be transported on the luminal surface of endothelial cells through transcytosis (50) and exert their activity directly on circulating DC precursors. In the perivascular space of inflamed CNS blood vessels, DCs may receive the necessary maturation signals from CNS-infiltrating T cells and either act locally to promote immune responses or migrate to draining lymph nodes to induce new waves of autoreactive T cells (19) . In the presence of high amounts of self-antigen released during CNS tissue destruction, a vicious circle may be established that would maintain immune reactivity through continuous trafficking and activation of DCs and T cells between the CNS and lymphoid organs.
CCL20 is expressed by surface-lining epithelial cells and epidermal cells and contributes to skin and mucosaassociated tissue immunity by attracting immature DCs, memory/effector T cells, and B cells through CCR6 (43, (51) (52) (53) . High levels of CCL20 have also been detected in rheumatoid arthritis synovial fluids and tissues (54, 55) and psoriatic skin (56) , suggesting a role for CCL20 in autoimmune diseases (for review, see (57) . In line with the present results, it has been shown that CCL20 released by IL1-b-and TNF-stimulated keratinocytes promotes the migration of CCR6+ Langerhans cell precursors in the inflamed epithelium (58) . Experimental evidence is also accumulating that CCL20 is involved in the development of CNS autoimmunity. Upregulation of CCL20 gene expression was previously demonstrated in rat experimental autoimmune panencephalomyelitis (59) . More recently, we reported that CCL20 is expressed in the spinal cord of EAE-affected mice by both infiltrating leukocytes and reactive astrocytes, and that murine astrocytes stimulated in vitro with inflammatory cytokines secrete biologically active CCL20 (16, 60) . Moreover, CCL20 plays an important role in immune priming during EAE and blockade of CCL20 activity with a neutralizing anti-CCL20 antibody reduces the clinical severity of the disease (61) . Given this experimental background, the present data suggest that intracerebrally produced CCL20 might also play a role in the local regulation of immune reactivity in the human disease, MS.
Chemokines binding to the promiscuous receptor CCR5, like CCL3, CCL4, and CCL5, have been shown to act as stimulators of immature DC migration (24) . All these chemokines are elevated in the CNS parenchyma and cerebrospinal fluid in several neuroinflammatory conditions and were previously shown to be produced by astrocytes in vitro and in situ (32) . The presence of CCR5 on DCs recruited into the cerebrospinal fluid and brain lesions of patients with MS (14, 18) favors the idea that this receptor is important for DC migration to the inflamed CNS. Our finding that CCR5 desensitization on iMDDC abrogates astrocyte-induced MDDC migration further supports a role for CCR5 and its ligands in the intracerebral recruitment of DCs.
CXCL12 is a chemokine that is constitutively expressed by stromal cells in the bone marrow, where it functions as a regulator of B cell lymphopoiesis, bone marrow myelopoiesis, and hematopoietic progenitor cell trafficking (62, 63) . CXCL12 is also expressed in the developing rodent brain, where it regulates neuronal progenitor cell migration and proliferation, and at lower levels in the adult brain, where it is thought to modulate neuronal activity and survival (64) . In vitro, CXCL12 expression has been reported in both neurons and astrocytes (64, 65) . Our data on the expression of CXCL12 in neurons and endothelial cells in the normal human CNS support a role for CXCL12 in brain physiology. Besides regulating homeostatic processes, CXCL12 and its receptor CXCR4 have been implicated in lymphocyte accumulation and retention in inflamed tissues and in the pathogenesis of autoimmune diseases (66) (67) (68) . Increased levels of CXCL12 have been detected in the cerebrospinal fluid of patients with MS and other inflammatory neurologic diseases (69) (70) (71) . CXCR4 is expressed on immature DCs, and at variance with other CC chemokine receptors that are downregulated during DC maturation, its expression levels remain elevated in mature DCs enabling migration toward CXCL12 (24, 25, 39) . Our findings that CXCL12 produced by human astrocytes attracts iMDDCs and that CXCL12 expression is increased in MS lesions, particularly in endothelial cells and astrocytes, support a role for this chemokine in the recruitment of DCs and other immune cell populations, like B cells, to the inflamed CNS. Given the effects of CXCL12 on neurons and neural cell progenitors (64) , increased CXCL12 production at CNS inflammatory sites could also play a role in the remodeling of functional neuronal circuits and in promoting repair processes.
In conclusion, these data complement and extend previous findings that indicate a key role for reactive astrocytes in shaping the composition of the inflammatory infiltrates in the diseased CNS. Because specific chemokines appear to be involved in DC recruitment to the CNS, blockade of their signaling pathways could be exploited to inhibit local DC-T cell interactions and, possibly, to prevent the amplification of destructive neuroinflammation in MS. 
